RESUMO
Testing for HIV is critical for early diagnosis of HIV infection, providing long-term good health for the individual and prevention of onward transmission if antiretroviral treatment is initiated early. The main purpose of the 2021 European Guideline on HIV Testing in Genito-Urinary Settings is to provide advice on testing for HIV infection in individuals aged 16 years and older who present to sexually transmitted infection, genito-urinary or dermato-venereology clinics across Europe. The guideline presents the details of best practice and offers practical guidance to clinicians and laboratories to identify and offer HIV testing to appropriate patient groups.
Assuntos
Infecções por HIV , Infecções Sexualmente Transmissíveis , Venereologia , Adolescente , Europa (Continente) , Infecções por HIV/diagnóstico , Infecções por HIV/tratamento farmacológico , Teste de HIV , HumanosRESUMO
OBJECTIVES: Routine HIV screening is recommended in those UK hospitals and primary care settings where the HIV prevalence is > 0.2%. For hepatitis B virus (HBV) and hepatitis C virus (HCV), however, testing is targeted at at-risk groups. We investigated the prevalence of these blood-borne viruses (BBVs) during a routine testing pilot in UK Emergency Departments (EDs). METHODS: During the "Going Viral" campaign (13-19 October 2014), nine UK EDs in areas of high HIV prevalence offered routine tests for HIV, HBV and HCV to adults having blood taken as part of routine care. Patients who tested positive were linked to care. RESULTS: A total of 7807 patients had blood taken during their ED visit; of these, 2118 (27%) were tested for BBVs (range 9-65%). Seventy-one BBV tests were positive (3.4%) with 32 (45.1%) new diagnoses. There were 39 HCV infections (15 newly diagnosed), 17 HIV infections (six newly diagnosed), and 15 HBV infections (11 newly diagnosed). Those aged 25-54 years had the highest prevalence: 2.46% for HCV, 1.36% for HIV and 1.09% for HBV. Assuming the cost per diagnosis is £7, the cost per new case detected would be £988 for HCV, £1351 for HBV and £2478 for HIV. CONCLUSIONS: In the first study in the UK to report prospectively on BBV prevalence in the ED, we identified a high number of new viral hepatitis diagnoses, especially hepatitis C, in addition to the HIV diagnoses. Testing for HIV alone would have missed 54 viral hepatitis diagnoses (26 new), supporting further evaluation of routine BBV testing in UK EDs.
Assuntos
Sangue/virologia , Infecções por HIV/diagnóstico , Hepatite B/diagnóstico , Hepatite C/diagnóstico , Programas de Rastreamento/métodos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Diagnóstico Precoce , Serviço Hospitalar de Emergência , Feminino , Infecções por HIV/economia , Infecções por HIV/epidemiologia , Hepatite B/economia , Hepatite B/epidemiologia , Hepatite C/economia , Hepatite C/epidemiologia , Humanos , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Prevalência , Estudos Prospectivos , Reino Unido/epidemiologia , Adulto JovemRESUMO
OBJECTIVES: Following national guidelines to expand HIV testing in high-prevalence areas in England, a number of pilot studies were conducted in acute general medical admission units (ACUs) and general practices (GPs) to assess the feasibility and acceptability of testing in these settings. The aim of this study was to estimate the cost per HIV infection diagnosed through routine HIV testing in these settings. METHODS: Resource use data from four 2009/2010 Department of Health pilot studies (two ACUs; two GPs) were analysed. Data from the pilots were validated and supplemented with information from other sources. We constructed possible scenarios to estimate the cost per test carried out through expanded HIV testing in ACUs and GPs, and the cost per diagnosis. RESULTS: In the pilots, cost per test ranged from £8.55 to £13.50, and offer time and patient uptake were 2 minutes and 90% in ACUs, and 5 minutes and 60% in GPs, respectively. In scenario analyses we fixed offer time, diagnostic test cost and uptake rate at 2 minutes, £6 and 80% for ACUs, and 5 minutes, £9.60 and 40% for GPs, respectively. The cost per new HIV diagnosis at a positivity of 2/1000 tests conducted was £3230 in ACUs and £7930 in GPs for tests performed by a Band 3 staff member, and £5940 in ACUs and £18 800 in GPs for tests performed by either hospital consultants or GPs. CONCLUSIONS: Expanded HIV testing may be more cost-efficient in ACUs than in GPs as a consequence of a shorter offer time, higher patient uptake, higher HIV positivity and lower diagnostic test costs. As cost per new HIV diagnosis reduces at higher HIV positivity, expanded HIV testing should be promoted in high HIV prevalence areas.
Assuntos
Custos e Análise de Custo/métodos , Testes Diagnósticos de Rotina/economia , Infecções por HIV/diagnóstico , Adolescente , Adulto , Idoso , Inglaterra , Medicina Geral/estatística & dados numéricos , Hospitalização/estatística & dados numéricos , Humanos , Programas de Rastreamento/economia , Pessoa de Meia-Idade , Projetos Piloto , Adulto JovemRESUMO
European guidelines recommend the routine offer of an HIV test in patients with a number of AIDS-defining and non-AIDS conditions believed to share an association with HIV; so called indicator conditions (IC). Adherence with this guidance across Europe is not known. We audited HIV testing behaviour in patients accessing care for a number of ICs. Participating centres reviewed the case notes of either 100 patients or of all consecutive patients in one year, presenting for each of the following ICs: tuberculosis, non-Hodgkins lymphoma, anal and cervical cancer, hepatitis B and C and oesophageal candidiasis. Observed HIV-positive rates were applied by region and IC to estimate the number of HIV diagnoses potentially missed. Outcomes examined were: HIV test rate (% of total patients with IC), HIV test accepted (% of tests performed/% of tests offered) and new HIV diagnosis rate (%). There were 49 audits from 23 centres, representing 7037 patients. The median test rate across audits was 72% (IQR 32-97), lowest in Northern Europe (median 44%, IQR 22-68%) and highest in Eastern Europe (median 99%, IQR 86-100). Uptake of testing was close to 100% in all regions. The median HIV+ rate was 0.9% (IQR 0.0-4.9), with 29 audits (60.4%) having an HIV+ rate >0.1%. After adjustment, there were no differences between regions of Europe in the proportion with >0.1% testing positive (global p = 0.14). A total of 113 patients tested HIV+. Applying the observed rates of testing HIV+ within individual ICs and regions to all persons presenting with an IC suggested that 105 diagnoses were potentially missed. Testing rates in well-established HIV ICs remained low across Europe, despite high prevalence rates, reflecting missed opportunities for earlier HIV diagnosis and care. Significant numbers may have had an opportunity for HIV diagnosis if all persons included in IC audits had been tested.
Assuntos
Sorodiagnóstico da AIDS/estatística & dados numéricos , Guias como Assunto , Europa (Continente)/epidemiologia , Infecções por HIV/diagnóstico , Infecções por HIV/epidemiologia , Humanos , Estudos RetrospectivosAssuntos
Terapia Antirretroviral de Alta Atividade , Infecções por HIV/terapia , Linfoma Relacionado a AIDS/terapia , Sarcoma de Kaposi/terapia , Neoplasias do Colo do Útero/terapia , Feminino , Infecções por HIV/complicações , Humanos , Imunoterapia , Linfoma Relacionado a AIDS/diagnóstico , Linfoma Relacionado a AIDS/virologia , Masculino , Estadiamento de Neoplasias , Prognóstico , Encaminhamento e Consulta , Sarcoma de Kaposi/diagnóstico , Sarcoma de Kaposi/virologia , Neoplasias do Colo do Útero/diagnóstico , Neoplasias do Colo do Útero/virologiaRESUMO
The overall purpose of these guidelines is to provide guidance on best clinical practice in the treatment and management of human immunodeficiency virus (HIV)-positive pregnant women in the UK. The scope includes guidance on the use of antiretroviral therapy (ART) both to prevent HIV mother-to-child transmission (MTCT) and for the welfare of the mother herself, guidance on mode of delivery and recommendations in specific patient populations where other factors need to be taken into consideration,such as coinfection with other agents. The guidelines are aimed at clinical professionals directly involved with, and responsible for, the care of pregnant women with HIV infection.
Assuntos
Fármacos Anti-HIV/uso terapêutico , Infecções por HIV/tratamento farmacológico , Transmissão Vertical de Doenças Infecciosas/prevenção & controle , Adulto , Terapia Antirretroviral de Alta Atividade , Parto Obstétrico/métodos , Feminino , HIV-1 , Humanos , Gravidez , Sociedades Médicas , Reino UnidoRESUMO
OBJECTIVES: Current British HIV Association (BHIVA) guidelines recommend that all patients with a CD4 count <350 cells/µL are offered highly active antiretroviral therapy (HAART). We identified risk factors for delayed initiation of HAART following a CD4 count <350 cells/µL. METHODS: All adults under follow-up in 2008 who had a first confirmed CD4 count <350 cells/µL from 2004 to 2008, who had not initiated treatment and who had >6 months of follow-up were included in the study. Characteristics at the time of the low CD4 cell count and over follow-up were compared to identify factors associated with delayed HAART uptake. Analyses used proportional hazards regression with fixed (sex/risk group, age, ethnicity, AIDS, baseline CD4 cell count and calendar year) and time-updated (frequency of CD4 cell count measurement, proportion of CD4 counts <350 cells/µL, latest CD4 cell count, CD4 percentage and viral load) covariates. RESULTS: Of 4871 patients with a confirmed low CD4 cell count, 436 (8.9%) remained untreated. In multivariable analyses, those starting HAART were older [adjusted relative hazard (aRH)/10 years 1.15], were more likely to be female heterosexual (aRH 1.13), were more likely to have had AIDS (aRH 1.14), had a greater number of CD4 measurements < 350 cells/µL (aRH/additional count 1.18), had a lower CD4 count over follow-up (aRH/50 cells/µL higher 0.57), had a lower CD4 percentage (aRH/5% higher 0.90) and had a higher viral load (aRH/log(10) HIV-1 RNA copies/ml higher 1.06). Injecting drug users (aRH 0.53), women infected with HIV via nonsexual or injecting drug use routes (aRH 0.75) and those of unknown ethnicity (aRH 0.69) were less likely to commence HAART. CONCLUSION: A substantial minority of patients with a CD4 count < 350 cells/µL remain untreated despite its indication.
Assuntos
Terapia Antirretroviral de Alta Atividade , Infecções por HIV/tratamento farmacológico , Infecções por HIV/imunologia , Adesão à Medicação , Adulto , Biomarcadores/análise , Contagem de Linfócito CD4 , Feminino , Seguimentos , Humanos , Masculino , Modelos de Riscos Proporcionais , Fatores de Risco , Reino UnidoAssuntos
Infecções por HIV/diagnóstico , Infecções por HIV/microbiologia , Infecções por HIV/prevenção & controle , Conhecimentos, Atitudes e Prática em Saúde , Homossexualidade Masculina/estatística & dados numéricos , Programas de Rastreamento/estatística & dados numéricos , Programas de Rastreamento/normas , Médicos/estatística & dados numéricos , Guias de Prática Clínica como Assunto , Tuberculose/virologia , Feminino , Humanos , MasculinoRESUMO
OBJECTIVE: The impact of different antiretroviral agents on the risk of developing or surviving CNS disease remains unknown. The aim of this study was to investigate whether using antiretroviral regimens with higher CNS penetration effectiveness (CPE) scores was associated with reduced incidence of CNS disease and improved survival in the UK Collaborative HIV Cohort (CHIC) Study. METHODS: Adults without previous CNS disease, who commenced combination antiretroviral therapy (cART) between 1996 and 2008, were included (n = 22,356). Initial and most recent cART CPE scores were calculated. CNS diseases were HIV encephalopathy (HIVe), progressive multifocal leukoencephalopathy (PML), cerebral toxoplasmosis (TOXO), and cryptococcal meningitis (CRYPTO). Incidence rates and overall survival were stratified by CPE score. A multivariable Poisson regression model was used to identify independent associations. RESULTS: The median (interquartile range) CPE score for initial cART regimen increased from 7 (5-8) in 1996-1997 to 9 (8-10) in 2000-2001 and subsequently declined to 6 (7-8) in 2006-2008. Differences in gender, HIV acquisition risk group, and ethnicity existed between CPE score strata. A total of 251 subjects were diagnosed with a CNS disease (HIVe 80; TOXO 59; CRYPTO 56; PML 54). CNS diseases occurred more frequently in subjects prescribed regimens with CPE scores ≤ 4, and less frequently in those with scores ≥ 10; however, these differences were nonsignificant. Initial and most recent cART CPE scores ≤ 4 were independently associated with increased risk of death. CONCLUSION: Clinical status at time of commencing cART influences antiretroviral selection and CPE score. This information should be considered when utilizing CPE scores for retrospective analyses.
Assuntos
Fármacos Anti-HIV/uso terapêutico , Doenças do Sistema Nervoso Central , Infecções por HIV/complicações , Infecções por HIV/tratamento farmacológico , Adulto , Antígenos CD4/metabolismo , Doenças do Sistema Nervoso Central/tratamento farmacológico , Doenças do Sistema Nervoso Central/etiologia , Doenças do Sistema Nervoso Central/virologia , Estudos de Coortes , Quimioterapia Combinada , Feminino , HIV/isolamento & purificação , Infecções por HIV/mortalidade , Humanos , Masculino , Análise de Regressão , Reprodutibilidade dos Testes , Estudos Retrospectivos , Fatores SexuaisAssuntos
Infecções por HIV/diagnóstico , Guias de Prática Clínica como Assunto , Instituições de Assistência Ambulatorial , Confidencialidade , Aconselhamento , HIV/genética , HIV/isolamento & purificação , Anticorpos Anti-HIV/sangue , Infecções por HIV/sangue , Infecções por HIV/virologia , Humanos , Cobertura do Seguro , Exposição Ocupacional , Reação em Cadeia da Polimerase , RNA Viral/genética , Reino UnidoRESUMO
We report a case of severe early congenital syphilis in the infant of a mother who acquired syphilis in mid pregnancy. The mother had received full antenatal care including serological screening for syphilis. Congenital syphilis is re-emerging in a number of industrialised countries and this report demonstrates that some of the most serious cases cannot be prevented by routine antenatal screening.
Assuntos
Transmissão Vertical de Doenças Infecciosas , Complicações Infecciosas na Gravidez/diagnóstico , Sífilis Congênita/diagnóstico , Sífilis/transmissão , Busca de Comunicante , Feminino , Humanos , Lactente , Masculino , Gravidez , Diagnóstico Pré-Natal , Sífilis/diagnóstico , Sorodiagnóstico da Sífilis , Reino UnidoRESUMO
A higher diploma is essential to progress in a career in hospital medicine. The MRCP (UK) and MRCPI are equivalent qualifications. However, there is little published information on the latter. This article reviews the key points regarding the MRCPI.
Assuntos
Mobilidade Ocupacional , Avaliação Educacional , Sociedades Médicas , Competência Clínica , Humanos , IrlandaRESUMO
The blood-taking practices and prevalence of needle-stick injuries were recorded for 46 house officers working at the two largest teaching hospitals in Sheffield and 38 house officers working at three hospitals in London. Wearing gloves when performing venesection or inserting an intravenous cannula was generally perceived as making the procedure more difficult and no house officer in either centre wore gloves when performing routine venesection. Twenty-five (54.3%) of the house officers from Sheffield resheathed needles by hand, while a further 14 (28.3%) placed the sheath onto a work surface before attempting to manoeuvre the needle back into its sheath. Only 7 (17.4%) house officers denied resheathing needles after performing venesection. Twenty-seven (58.7%) admitted to having had a needle-stick injury within 3 months of commencing their first house officer post. Twenty-seven (71.1%) of the house officers from London resheathed needles, the remainder disposing of the needle by placing it straight into an appropriate container. Twenty-five (66%) admitted to having had a needle-stick injury the first 6 months of being a house officer. Training in the correct techniques of venesection with emphasis on either avoiding resheathing needles or resheathing safely is essential early in the medical student curriculum and needs regular repetition.